Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.
Sign up now!
Real World Evidence and Claims Databases – a Guide for Healthcare Professionals
Prof. Craig I. Coleman gives an appreciation of the methodology used to perform Real World Evidence studies, particularly those investigating the effectiveness and safety, of non-vitamin K antagonist oral anticoagulants (or NOACs) in non-valvular atrial fibrillation patients. He also provides some key insights on what real world evidence and specifically claims databases can - and cannot - tell us.
Approval Number PP-XAR-ALL-0036-2
For more information visit:
Dresden NOAC Registry (site in German): (Accessed 9 November 2020)
Clinicaltrials.gov (Accessed 9 November 2020)
Related key publications:
Helmert S, Marten S, Mizera H et al. Effectiveness and safety of apixaban therapy in dailycare patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis 2017;44:169–178.
Hecker J, Marten S, Keller L et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016;115:939–949.
Beyer-Westendorf J, Ebertz F, Förster K et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113:1247–1257.
Beyer-Westendorf J, Förster K, Ebertz F et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015; 17:530–538.
Michalski F, Tittl L, Werth S et al. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC Registry. Thromb Haemost 2015;114:1076–1084.
Beyer-Westendorf J, Förster K, Pannach S et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC Registry. Blood 2014; 124:955–962.
Beyer-Westendorf J, Gelbricht V, Förster K et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC Registry. Eur Heart J 2014;35:1888–1896.
Beyer-Westendorf J, Gelbricht V, Förster K et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care–results from the Dresden NOAC Registry. Br J Clin Pharmacol. 2014;78:908–917.
For more information visit:
Thrombosis Research Institute (Accessed 9 November 2020)
Clinicaltrials.gov (Accessed 9 November 2020)
Related key publications:
Bassand JP, Accetta G, Al Mahmeed W et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One 2018;13:e0191592.
Fox KAA, Accetta G, Pieper KS et al. Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Eur Heart J Qual Care Clin Outcomes 2018;4:27–35.
Verheugt FWA, Gao H, Al Mahmeed W et al. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J 2018;39:464–473.
Camm AJ, Accetta G, Al Mahmeed W et al. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open 2017;7:e014579.
Fox KAA, Gersh BJ, Traore S et al. Evolving quality standards for large-scale registries: the GARFIELD-AF experience. Eur Heart J Qual Care Clin Outcomes 2017;3:114–122.
Fitzmaurice DA, Accetta G, Haas S et al. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol 2016;174:610–623.
Haas S, Ten Cate H, Accetta G et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One 2016;11:e0164076.
Stępińska J, Kremis E, Konopka A et al. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry. Kardiol Pol 2016;74:362–371.
Lip GYH, Rushton-Smith SK, Goldhaber SZ et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 2015;8:S12–S20.
Kakkar AK, Mueller I, Bassand JP et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013;8:e63479.
Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012;163:13–19.e1.
Related key publications:
Darrat YH, Shah J, Elayi CS et al. Regional lack of consistency in the management of atrial fibrillation (from the RECORD-AF trial). Am J Cardiol 2017;119:47–51.
Ha AC, Breithardt G, Camm AJ et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF). Circ Cardiovasc Qual Outcomes 2014;7:896–904.
Opolski G, Kosior DA, Kurzelewski M et al. One-year follow-up of the Polish subset of the RecordAF registry of patients with newly diagnosed atrial fibrillation. Pol Arch Med Wewn 2013;123:238–245.
Zhang YY, Qiu C, Davis PJ et al. Predictors of progression of recently diagnosed atrial fibrillation in REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation (RecordAF)-United States cohort. Am J Cardiol 2013;112:79–84.
De Vos CB, Breithardt G, Camm AJ et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 2012;163:887–893.
Camm AJ, Breithardt G, Crijns H et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol 2011;58:493–501.
Le Heuzey JY, Breithardt G, Camm J et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 2010;105:687–693.
For more information visit:
ORBIT-AF I Clinicaltrials.gov record (Accessed 9 November 2020)
ORBIT-AF II Clinicaltrials.gov record (Accessed 9 November 2020)
Related key publications:
O'Brien EC, Holmes DN, Thomas LE et al. Prognostic significance of nuisance bleeding in anticoagulated patients with atrial fibrillation. Circulation 2018: doi:10.1161/CIRCULATIONAHA.117.031354.
O'Brien EC, Holmes DN, Thomas L et al. Therapeutic strategies following major, clinically relevant nonmajor, and nuisance bleeding in atrial fibrillation: findings from ORBIT-AF. J Am Heart Assoc 2018;7:e006391.
Steinberg BA, Shrader P, Pieper K et al. Frequency and outcomes of reduced dose nonvitamin k antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc 2018;7:e007633.
Barnett AS, Kim S, Fonarow GC et al. Treatment of atrial fibrillation and concordance with the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: findings from ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol 2017;10:e005051.
Black-Maier, Kim S, Steinberg BA et al. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol 2017;40:746–751.
Cherian TS, Shrader P, Fonarow GC et al. Effect of atrial fibrillation on mortality, stroke risk, and quality-of-life scores in patients with heart failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Am J Cardiol 2017;119:1763–1769.
Echouffo-Tcheugui JB, Shrader P, Thomas L et al. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. J Am Coll Cardiol 2017;70:1325–1335.
Hess PL, Kim S, Fonarow GC et al. Absence of oral anticoagulation and subsequent outcomes among outpatients with atrial fibrillation. Am J Med 2017;130:449–456.
Melloni C, Shrader P, Carver J et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 2017;3:192–197.
Pandey A, Kim S, Moore C et al. Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation. JACC Heart Fail 2017;5:44–52.
Pokorney SD, Kim S, Thomas L et al. Cardioversion and subsequent quality of life and natural history of atrial fibrillation. Am Heart J 2017;185:59–66.
Steinberg BA, Gao H, Shrader P et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J 2017;194:132–140.
Steinberg BA, Shrader P, Thomas L et al. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J 2017;189:40–47.
Steinberg BA, Simon DN, Thomas L et al. Management of major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants compared with warfarin in clinical practice (from phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Am J Cardiol 2017;119:1590–1595.
Thomas KL, Jackson LR 2nd, Shrader P et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation). J Am Heart Assoc 2017;6:e006475.
Golwala H, Jackson LR 2nd, Simon DN et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation registry. Am Heart J 2016;174:29–36.
Gundlund A, Fosbøl EL, Kim S et al. Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2016;175:28–35.
Piccini JP, Simon DN, Steinberg BA et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. JAMA Cardiol 2016;1:282–291.
Randolph TC, Simon DN, Thomas L et al. Patient factors associated with quality of life in atrial fibrillation. Am Heart J 2016;182:135–143.
Steinberg BA, Shrader P, Kim S et al. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2016;181:145–152.
Steinberg BA, Shrader P, Thomas L et al. Off-Label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016;68:2597–2604.
O'Brien EC, Holmes DN, Ansell JE et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2014;167:601–609.
Steinberg BA, Blanco RG, Ollis D et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J 2014;168:160–167.
Cullen MW, Kim S, Piccini JP Sr et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 2013;6:461–469.
Fosbol EL, Holmes DN, Piccini JP et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc 2013;2:e000110.
Hess PL, Kim S, Piccini JP et al. Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med 2013;126:625–632.e1.
Steinberg BA, Holmes DN, Ezekowitz MD et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J 2013;165:622–629.
Steinberg BA, Holmes DN, Piccini JP et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. J Am Heart Assoc 2013;2:e000535.
Steinberg BA, Kim S, Piccini JP et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 2013;128:721–728.
Piccini JP, Fraulo ES, Ansell JE et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011;162:606–612.e1.
Objectives:
For more information visit:
Centers for Disease Control and Prevention (Accessed 9 November 2020)
Related key publications:
Tong X, George MG, Yang Q et al. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012. Int J Stroke 2014;9:728–734.
Nickles A, Fiedler J, Roberts S et al. Compliance with the stroke education performance measure in the Michigan Paul Coverdell National Acute Stroke Registry. Stroke 2013;44:1459–1462.
Centers for Disease Control and Prevention (CDC). Use of a registry to improve acute stroke care–seven states, 2005-2009. MMWR Morb Mortal Wkly Rep 2011;60:206–210.
Reeves MJ, Gargano J, Maier KS et al. Patient-level and hospital-level determinants of the quality of acute stroke care: a multilevel modeling approach. Stroke 2010;41:2924–2931.
Centers for Disease Control and Prevention. 2009. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5807a1.htm [Accessed 19 November 2020].
George MG, Tong X, McGruder H et al. Paul Coverdell National Acute Stroke Registry Surveillance – four states, 2005–2007. MMWR Surveill Summ 2009;58:1–23.
For more information visit:
GLORIA-AF phase I Clinicaltrials.gov (Accessed 9 November 2020)
GLORIA-AF phases II and III Clinicaltrials.gov (Accessed 9 November 2020)
Related key publications:
Huisman MV, Rothman KJ, Paquette M et al. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J 2018;198:55–63.
Mazurek M, Huisman MV, Rothman KJ et al. Gender differences in antithrombotic treatment for newly diagnosed atrial fibrillation: the GLORIA-AF registry program. Am J Med 2018;131:945–955.
Mazurek M, Huisman MV, Rothman KJ et al. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF phase II registry. Thromb Haemost 2017;117:2376–2388.
McIntyre WF, Conen D, Olshansky B et al. Stroke-prevention strategies in North American patients with atrial fibrillation: the GLORIA-AF registry program. Clin Cardiol 2018;41:744–751.
Huisman MV, Rothman KJ, Paquette M et al. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 2017;69:777–785.
Huisman MV, Ma CS, Diener HC et al. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) phase I cohort. Europace 2016;18:1308–1318.
Huisman MV, Rothman KJ, Paquette M et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry, phase II. Am J Med 2015;128:1306–1313.
Huisman MV, Lip GYH, Diener HC et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J 2014;167:329–334.
Related key publications:
Chiang CE, Naditch-Brûlé L, Brette S et al. Atrial fibrillation management strategies in routine clinical practice: insights from the international RealiseAF survey. PLoS One 2016;11:e0147536.
Narasimhan C, Verma JS, Ravi Kishore AG et al. Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. Indian Heart J 2016;68:663–670.
Gamra H, Murin J, Chiang CE et al. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis 2014;107:77–87.
Murin J, Naditch-Brûlé L, Brette S et al. Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One 2014;9:e86443.
Wang KL, Wu CH, Huang CC et al. Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort. J Cardiol 2014;64:211–217.
Chiang CE, Goethals M, O'Neill JO et al. Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. Europace 2013;15:1733–1740.
Silva-Cardoso J, Zharinov OJ, Ponikowski P et al. Heart failure in patients with atrial fibrillation is associated with a high symptom and hospitalization burden: the RealiseAF survey. Clin Cardiol 2013;36:766–774.
Chiang CE, Naditch-Brûlé L, Murin J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632–639.
Alam M, Bandeali SJ, Shahzad SA et al. Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Rev Cardiovasc Ther 2012;10:283–291.
Steg PG, Alam S, Chiang CE et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 2012;98:195–201.
Related key publications:
De Caterina R, Brüggenjürgen B, Darius H et al. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: a PREFER in AF registry substudy. Arch Cardiovasc Dis 2018;111:74–84.
Schnabel RB, Pecen L, Engler D et al. Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. Heart 2018;104:1608–1614.
Siller-Matula JM, Pecen L, Patti G et al. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. Int J Cardiol 2018;265:141–147.
Hanon O, Vidal JS, Le Heuzey JY et al. Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. Int J Cardiol 2017;232:98–104.
Patti G, Lucerna M, Cavallari I et al. Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF. J Am Coll Cardiol 2017;69:409–419.
Patti G, Lucerna M, Pecen L et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc 2017;6:e005657.
Schnabel RB, Pecen L, Ojeda FM et al. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart 2017;103:1024–1030.
Bakhai A, Darius H, De Caterina R et al. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. Eur Heart J Qual Care Clin Outcomes 2016;2:299–305.
Renda M, Schilling R, Le Heuzey JY et al. Antithrombotic management of atrial fibrillation: follow-up data from the PREFER in AF registry. Eur Heart J 2016;37:494–5: Abstract P2548.
Brüggenjürgen B, Schliephacke T, Darius H et al. Discontinuation and hospitalisation rates in patients with atrial fibrillation: follow-up results of the PREFER in AF registry. Value Health 2014;17:A473. Abstract PCV2.
Brüggenjürgen B, Schliephacke T, Darius H et al. Health state in patients with atrial fibrillation on new oral anticoagulants as assessed with the new EQ-5D-5L questionnaire at baseline and 12-month follow-up: PREFER in AF registry. Value Health 2014;17:A493. Abstract PCV120.
Brüggenjürgen B, Schliephacke T, Darius H et al. Treatment satisfaction in patients with atrial fibrillation on new oral anticoagulants as assessed with PACT-Q2 at baseline and 12-month follow-up: PREFER in AF registry. Value Health 2014;17:A497. Abstract PCV140.
De Caterina R, Ammentorp B, Darius H et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart 2014;100:1625–1635.
Kirchhof P, Ammentorp B, Darius H et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6–14.
Le Heuzey JY, Ammentorp B, Darius H et al. Differences among Western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014;111:833–841.
For more information visit:
Kompetenznetz Vorhofflimmern (Site in German) (Accessed 9 November 2020)
Related key publications:
Haeusler KG, Gerth A, Limbourg T et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. BMC Neurol 2015;15:129.
Kirchhof P, Nabauer M, Gerth A et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011;105:1010–1023.
Nabauer M, Gerth A, Limbourg T et al. The registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423–434.
XANTUS pooled: global rivaroxaban use in real-world patients with non-valvular atrial fibrillation
The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe
© Bayer AG, 2017 | Approval Number PP-XAR-ALL-0639-1
For more information visit:
Clinicaltrials.gov (Accessed 9 November 2020)
Related key publications:
Camm AJ, Turpie AGG, Hess S et al. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. Europace 2018;20:e87–e95.
Camm AJ, Amarenco P, Haas S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145–1153.
Coleman CI, Haas S, Turpie AGG et al. Impact of switching from a vitamin k antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin Cardiol 2016;39:565–569.
Camm AJ, Amarenco P, Haas S et al. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag 2014;10:425–434.